Product Description
| Product Name | Erlotinib N-3-bromophenyl Analog |
| CAS Number | 2055840-41-8 (HCl Salt); 328528-74-1 (Base) |
| Synonyms | N-(3-Desethynylphenyl)-N-(3-bromophenyl) Erlotinib Hydrochloride; N-(3-bromophenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Hydrochloride |
| Catalog Number | SA25212 |
| Molecular Formula | C20H22BrN3O4.HCl |
| Molecular Weight | 484.77 |
| Related API | Erlotinib |
| Category | Impurities |
Order Erlotinib N-3-bromophenyl Analog product with CAS: 2055840-41-8 (HCl Salt); 328528-74-1 (Base) and speed up your Erlotinib project. This product is also known as N-(3-Desethynylphenyl)-N-(3-bromophenyl) Erlotinib Hydrochloride; N-(3-bromophenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Hydrochloride and can be used as working standard or secondary reference standard. Additional internal validation as per respective FDA regulations/guidelines may require. This product provided by SynThink is generally used for Abbreviated New Drug Application (ANDA), Drug Master File (DMF) filing, toxicity study of respective drug formulation, Quality Control (QC) and analytical studies during commercial production of Erlotinib. Please also find out other Erlotinib related compounds developed by our R&D.
Quantity / packs as per your requirement, just let us know! For different pack size / quantity, please click here contact us or email us at enquiry@synthinkchemicals.com.
All products are provided with certificate of analysis (CoA) along with the characterization data like 1H-NMR, MASS, HPLC Purity, MSDS (whatever relevant and possible). Moreover, additional data like 13C-NMR, 13C-DEPT NMR, GC, GC-MS, IC, Potency, TGA, etc. will be provided on request (extra charges may apply). Products provide by SynThink are for research and development (R&D) use only.
Keywords : Price of Erlotinib N-3-bromophenyl Analog, CAS: 2055840-41-8 (HCl Salt); 328528-74-1 (Base), N-(3-Desethynylphenyl)-N-(3-bromophenyl) Erlotinib Hydrochloride SUPPLIER, Erlotinib impurity manufacturer, Erlotinib related compound.
